Serina Therapeutics, Inc. (SER) stock

SERNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30

$1.39−0.02 (-1.42%)

Close on Nov 13, 2026Market cap $35.31MP/E –Yield –

Serina Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Serina Therapeutics's price to book ratio was 19.5× on Jan 30, 2026, against 14.3× a year earlier. Over the last 3 years it ranged from 8.7× to 92.8×, with a median of 19.5×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Jan 30, 2026	19.5×	+8.0
2025	Dec 31, 2025	11.5×	−2.9
2020	Apr 30, 2020	14.3×	−1.5
2019	Dec 31, 2019	15.8×	+1.9
2018	Dec 31, 2018	13.9×	–

Where these numbers come from

Parsed from the XBRL in Serina Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing